RADXNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as RDPTF

Radiopharm Theranostics Ltd

Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Sep 30, 2026

$0.96−0.07 (-6.50%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Jun 30, 2025

Radiopharm Theranostics reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Radiopharm Theranostics's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Radiopharm Theranostics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is RADX.

Company	Revenue	Growth
PCT	$13.76M	+326.1%
RADX	$3.63M	+1114.3%
PPCB	–	–
AKTX	–	–
HSTC	$0	–
SNY	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: June 30
Employees: 2
Auditor: GRANT THORNTON AUDIT PTY LTD
SEC CIK: 1949257

Advertisement
300 × 250